Misplaced Pages

Vilobelimab, sold under the brand name Gohibic, is a monoclonal antibody that is used for the treatment of COVID-19. It is a human-mouse chimeric IgG4 kappa antibody that targets human C5a in plasma.

The most common adverse reactions include pneumonia, sepsis, delirium, pulmonary embolism, hypertension, pneumothorax, deep vein thrombosis, herpes simplex, enterococcal infection, bronchopulmonary aspergillosis, hepatic enzyme increased, urinary tract infection, hypoxia, thrombocytopenia, pneumomediastinum, respiratory tract infection, supraventricular tachycardia, constipation, and rash.

Vilobelimab is a recombinant chimeric monoclonal IgG4 antibody that specifically binds to the soluble human complement split product C5a after cleavage from C5 to block its interaction with the C5a receptor, both of which are components of the complement system thought to contribute to inflammation and worsening of COVID-19. Vilobelimab was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in April 2023. Vilobelimab was approved for medical use in the European Union in January 2025.

Medical uses

In the US, vilobelimab is authorized via an emergency use authorization for use in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation or extracorporeal membrane oxygenation (artificial life support). Vilobelimab is not approved by the US Food and Drug Administration (FDA) for any indication, including for the treatment of COVID-19.

In the EU, vilobelimab is indicated for the treatment of adults with SARS-CoV-2 induced acute respiratory distress syndrome who are receiving systemic corticosteroids as part of standard of care and receiving invasive mechanical ventilation (with or without extracorporeal membrane oxygenation).

History

The clinical trial supporting the authorization showed that participants treated with vilobelimab had a lower risk of death by day 28 and day 60 of treatment compared to placebo.

Society and culture

Legal status

In November 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Gohibic intended for the treatment of adults with SARS‑CoV2‑induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids. The applicant for this medicinal product is InflaRx GmbH. Vilobelimab was approved for medical use in the European Union in January 2025.

Names

Vilobelimab is the international nonproprietary name.

References

1. ^ "Gohibic- vilobelimab injection". DailyMed. 16 May 2023. Retrieved 16 January 2025.
2. ^ "Gohibic EPAR". European Medicines Agency (EMA). 14 November 2024. Retrieved 16 November 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
3. ^ "Gohibic PI". Union Register of medicinal products. 14 January 2025. Retrieved 16 January 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
4. ^ "FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19". U.S. Food and Drug Administration (FDA). 4 April 2023. Retrieved 4 April 2023. This article incorporates text from this source, which is in the public domain.
5. ^ https://www.fda.gov/media/166824/download
6. ^ https://www.fda.gov/media/166823/download This article incorporates text from this source, which is in the public domain.
7. https://www.fda.gov/media/166826/download
8. "InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients" (Press release). InflaRx N.V. 4 April 2023. Retrieved 4 April 2023 – via GlobeNewswire.
9. "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2024". European Medicines Agency (EMA). 15 November 2024. Retrieved 16 November 2024.
10. World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 84". WHO Drug Information. 34 (3). hdl:10665/340680.

Further reading

• Vlaar AP, Witzenrath M, van Paassen P, Heunks LM, Mourvillier B, de Bruin S, et al. (December 2022). "Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial". The Lancet. Respiratory Medicine. 10 (12): 1137–1146. doi:10.1016/S2213-2600(22)00297-1. PMC 9451499. PMID 36087611.{{cite journal}}: CS1 maint: overridden setting (link)

External links

• Clinical trial number NCT04333420 for "Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia (PANAMO)" at ClinicalTrials.gov

• Medicine
• Viruses
• COVID-19

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Antiviral drugs
• Experimental antiviral drugs
• COVID-19 drug development
• Monoclonal antibodies
• Pharmacology stubs